Bio-Techne Corporation will present at three investor conferences in December 2025, including the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and the Nasdaq Investor Conference.
These presentations will be accessible via a live webcast on Bio-Techne's Investor Relations website, allowing investors to gain insights into the company's future direction and innovations.
As a global life sciences company, Bio-Techne provides innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.2 billion in net sales in fiscal 2025.
With approximately 3,100 employees and a diverse portfolio of products, Bio-Techne continues to support scientific investigations and clinical testing, positioning itself as a leader in the life sciences sector.
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 66.14 USD with a low forecast of 60.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 66.14 USD with a low forecast of 60.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 65.560
Low
60.00
Averages
66.14
High
72.00
Current: 65.560
Low
60.00
Averages
66.14
High
72.00
Evercore ISI
Outperform -> In Line
downgrade
$68 -> $62
2026-01-05
Reason
Evercore ISI
Price Target
$68 -> $62
AI Analysis
2026-01-05
downgrade
Outperform -> In Line
Reason
Evercore ISI downgraded Bio-Techne to In Line from Outperform with a price target of $62, down from $68.
Deutsche Bank
Justin Bowers
Buy
maintain
$66 -> $72
2025-12-12
Reason
Deutsche Bank
Justin Bowers
Price Target
$66 -> $72
2025-12-12
maintain
Buy
Reason
Deutsche Bank analyst Justin Bowers raised the firm's price target on Bio-Techne to $72 from $66 and keeps a Buy rating on the shares. The firm cites accretion prospects of Bio-Techne's acquisition of Wilson Wolf for the target increase.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TECH
Unlock Now
Baird
Catherine Ramsey Schulte
Neutral
downgrade
$62 -> $61
2025-11-06
Reason
Baird
Catherine Ramsey Schulte
Price Target
$62 -> $61
2025-11-06
downgrade
Neutral
Reason
Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Bio-Techne to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
UBS
Buy
maintain
$65 -> $70
2025-11-06
Reason
UBS
Price Target
$65 -> $70
2025-11-06
maintain
Buy
Reason
UBS raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares.
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
